Nastech Pharmaceuticals (NSTK - Cramer’s Take - Stockpickr - Rating) received a small bounce Wednesday after announcing a corporate restructuring and cost-cutting plan precipitated by the Nov. 6 decision by Proctor & Gamble (PG - Cramer’s Take - Stockpickr - Rating) to return rights to the nasal spray for osteoporosis.
